TY - JOUR
T1 - HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial
T2 - a qualitative longitudinal study, South Africa
AU - On behalf of the PrEPVacc Study Group
AU - Chimukuche, Rujeko Samanthia
AU - Shandu, Londiwe
AU - Zulu, Silindile
AU - Khanyile, Phindile
AU - Singh, Nishanta
AU - Gaffoor, Zakir
AU - Kawuma, Rachel
AU - McCormack, Sheena
AU - Seeley, Janet
AU - Gray, Glenda
AU - Singh, Nishanta
AU - Gaffoor, Zakir
AU - Morar, Neetha
AU - Sithole, Thandiwe
AU - Woeber, Kubashni
AU - Siva, Samantha
AU - Hwengwere, Eldinah
AU - Chidawanyika, Rujeko Samanthia
AU - Mahapa, Nteboheleng
AU - Khanyile, Phindile
AU - Jani, Ilesh
AU - Viegas, Edna
AU - Remane, Isabel
AU - Bule, Odete
AU - Nhacule, Edna
AU - Ramgi, Patricia
AU - Chissumba, Raquel
AU - Namalango, Eduardo
AU - Manganhe, Yolanda
AU - Massingue, Carmelia
AU - Capitine, Igor
AU - Ribeiro, Jorge
AU - Maganga, Lucas
AU - William, Wiston
AU - Kapesa, Emmanuel
AU - Danstan, Elizabeth
AU - Pamba, Doreen
AU - Missanga, Marco
AU - Kway, Amani
AU - Kisinda, Abisai
AU - Njovu, Lilian
AU - Sudi, Lwitiho
AU - Kunambi, Revocatus
AU - Aboud, Said
AU - Munseri, Patricia
AU - Lyamuya, Eligius
AU - Msafiri, Frank
AU - Joachim, Agricola
AU - Tarimo, Edith
AU - Robb, Merlin
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025.
PY - 2025/4/23
Y1 - 2025/4/23
N2 - Introduction Ensuring the effectiveness of HIV prevention and treatment methods requires high levels of adherence. Studies have recognised the significance of trust in shaping HIV risk perception. Aim In this qualitative analysis, our aim was to explore risk perceptions and understand how individuals assess and respond to HIV risks, as well as their uptake and adherence to oral pre-exposure prophylaxis (PrEP). Setting The study was based on the setting of an HIV prevention trial conducted in South Africa. Methods Thirty individuals, 9% of the total clinical trial participants, enrolled in the clinical trial were purposively selected and interviewed at three time points within the trial during the follow-up phase. Data analysis was conducted using the Trust, Confidence and Cooperation framework that included constructs of trust, confidence and cooperation. Results The findings show that the ongoing participation in the clinical trial played a significant role in influencing participants’ decision to continue PrEP as HIV prevention. This decision was grounded in their trust that PrEP would effectively reduce their vulnerability to HIV and infection. Conclusion Clear and consistent health-promoting initiatives enhance participants’ self-awareness of HIV risks and promote understanding (uptake) and effectiveness of HIV prevention methods.
AB - Introduction Ensuring the effectiveness of HIV prevention and treatment methods requires high levels of adherence. Studies have recognised the significance of trust in shaping HIV risk perception. Aim In this qualitative analysis, our aim was to explore risk perceptions and understand how individuals assess and respond to HIV risks, as well as their uptake and adherence to oral pre-exposure prophylaxis (PrEP). Setting The study was based on the setting of an HIV prevention trial conducted in South Africa. Methods Thirty individuals, 9% of the total clinical trial participants, enrolled in the clinical trial were purposively selected and interviewed at three time points within the trial during the follow-up phase. Data analysis was conducted using the Trust, Confidence and Cooperation framework that included constructs of trust, confidence and cooperation. Results The findings show that the ongoing participation in the clinical trial played a significant role in influencing participants’ decision to continue PrEP as HIV prevention. This decision was grounded in their trust that PrEP would effectively reduce their vulnerability to HIV and infection. Conclusion Clear and consistent health-promoting initiatives enhance participants’ self-awareness of HIV risks and promote understanding (uptake) and effectiveness of HIV prevention methods.
UR - https://www.scopus.com/pages/publications/105003981866
U2 - 10.1136/bmjopen-2024-086742
DO - 10.1136/bmjopen-2024-086742
M3 - Article
C2 - 40268488
AN - SCOPUS:105003981866
SN - 2044-6055
VL - 15
JO - BMJ Open
JF - BMJ Open
IS - 4
M1 - e086742
ER -